
ERK1/2 activation is a therapeutic target in age-related macular degeneration
Author(s) -
Sami Dridi,
Yoshio Hirano,
Valeria Tarallo,
Younghee Kim,
Benjamin J. Fowler,
Balamurali K. Ambati,
Sasha Bogdanovich,
Vince A. Chiodo,
William W. Hauswirth,
Jennifer F. Kugel,
James A. Goodrich,
Steven L. Ponicsan,
David R. Hinton,
Mark E. Kleinman,
Judit Baffi,
Bradley D. Gelfand,
Jayakrishna Ambati
Publication year - 2012
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1206494109
Subject(s) - macular degeneration , kinase , microbiology and biotechnology , gene knockdown , biology , mapk/erk pathway , p38 mitogen activated protein kinases , retinal pigment epithelium , phosphorylation , ribonuclease iii , cancer research , rna , retina , cell culture , medicine , rna interference , genetics , neuroscience , gene , ophthalmology
Deficient expression of the RNase III DICER1, which leads to the accumulation of cytotoxic Alu RNA, has been implicated in degeneration of the retinal pigmented epithelium (RPE) in geographic atrophy (GA), a late stage of age-related macular degeneration that causes blindness in millions of people worldwide. Here we show increased extracellular-signal-regulated kinase (ERK) 1/2 phosphorylation in the RPE of human eyes with GA and that RPE degeneration in mouse eyes and in human cell culture induced by DICER1 depletion or Alu RNA exposure is mediated via ERK1/2 signaling. Alu RNA overexpression or DICER1 knockdown increases ERK1/2 phosphorylation in the RPE in mice and in human cell culture. Alu RNA-induced RPE degeneration in mice is rescued by intravitreous administration of PD98059, an inhibitor of the ERK1/2-activating kinase MEK1, but not by inhibitors of other MAP kinases such as p38 or JNK. These findings reveal a previously unrecognized function of ERK1/2 in the pathogenesis of GA and provide a mechanistic basis for evaluation of ERK1/2 inhibition in treatment of this disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom